Kexing Biopharm Future Growth
Future criteria checks 5/6
Kexing Biopharm is forecast to grow earnings and revenue by 99.5% and 26.1% per annum respectively. EPS is expected to grow by 99.8% per annum. Return on equity is forecast to be 8.9% in 3 years.
Key information
99.5%
Earnings growth rate
99.8%
EPS growth rate
| Biotechs earnings growth | 34.3% |
| Revenue growth rate | 26.1% |
| Future return on equity | 8.9% |
| Analyst coverage | Low |
| Last updated | 29 Apr 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2,692 | 257 | N/A | 337 | 1 |
| 12/31/2025 | 1,984 | 135 | N/A | 178 | 2 |
| 12/31/2024 | 1,491 | 44 | N/A | 42 | 2 |
| 3/31/2024 | 1,297 | -169 | -238 | -47 | N/A |
| 12/31/2023 | 1,259 | -190 | -278 | -87 | N/A |
| 9/30/2023 | 1,341 | -90 | -310 | -55 | N/A |
| 6/30/2023 | 1,335 | -141 | -413 | -139 | N/A |
| 3/31/2023 | 1,369 | -128 | -456 | -122 | N/A |
| 12/31/2022 | 1,316 | -90 | -485 | -86 | N/A |
| 9/30/2022 | 1,333 | -37 | -554 | -81 | N/A |
| 6/30/2022 | 1,319 | 39 | -549 | -19 | N/A |
| 3/31/2022 | 1,278 | 79 | -385 | 48 | N/A |
| 12/31/2021 | 1,285 | 96 | -278 | 94 | N/A |
| 9/30/2021 | 1,225 | 97 | -198 | 108 | N/A |
| 6/30/2021 | 1,250 | 105 | -80 | 135 | N/A |
| 3/31/2021 | 1,152 | 100 | -71 | 126 | N/A |
| 12/31/2020 | 1,220 | 139 | -83 | 106 | N/A |
| 9/30/2020 | 1,220 | 158 | -28 | 98 | N/A |
| 12/31/2019 | 1,191 | 160 | -48 | 5 | N/A |
| 12/31/2018 | 891 | 94 | 23 | 63 | N/A |
| 12/31/2017 | 616 | 59 | N/A | 65 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688136 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.9%).
Earnings vs Market: 688136 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 688136 is expected to become profitable in the next 3 years.
Revenue vs Market: 688136's revenue (26.1% per year) is forecast to grow faster than the CN market (14.6% per year).
High Growth Revenue: 688136's revenue (26.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688136's Return on Equity is forecast to be low in 3 years time (8.9%).